Efficacy of Antibiotic Prophylaxis after Endobronchial Ultrasound-guided Transbronchial Needle Aspiration: A Preliminary Prospective Study

Haruhi Takagi¹, Tetsutaro Nagaoka¹, Katsutoshi Ando¹, Takeo Tsutsumi¹, Masako Ichikawa¹, Ryo Koyama¹, Naoko Shimada¹, Kazunori Tobino² and Kazuhsa Takahashi³

¹Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
²Department of Respiratory Medicine, Iizuka Hospital, Fukuoka, Japan

Abstract

Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is useful for diagnosing mediastinal and hilar lymphadenopathy. While bacteremia and serious infectious complications after EBUS-TBNA have been reported, the efficacy of antibiotic prophylaxis is unclear. This preliminary prospective study aimed to evaluate the efficacy of antibiotic prophylaxis after EBUS-TBNA.

Methods: Patients were randomly assigned to the antibiotic group (n = 43) or control group (n = 47). Ampicillin/sulbactam was intravenously administered before the puncture, followed by oral amoxicillin/clavulanate. The primary outcome was body temperature (BT) within 5 days after EBUS-TBNA. The secondary outcomes were the change in the white blood cell count (WBC) and C-reactive protein (CRP) value before and after the examination, and the frequency of infectious complications that required antibiotics. We also assessed the clinical characteristics of patients with fever.

Results: BT after EBUS-TBNA did not significantly differ between the groups. Antibiotic prophylaxis had no effect on the changes in the WBC and CRP value. Neither group had infectious complications associated with EBUS-TBNA. The smoking pack-year was higher in the group with fever than without fever, although the WBC and CRP value at baseline were similar between the groups. The number of punctures, presence of low-density areas in the lymph nodes, and antibiotic treatment were unrelated to the development of fever following EBUS-TBNA.

Conclusion: Results of this study and the low frequency of infectious complications, which has been demonstrated in previous reports, suggest that antibiotic prophylaxis is not recommended for EBUS-TBNA (UMIN: 000008813).

Keywords: Antibiotics; Endobronchial ultrasound-guided transbronchial needle aspiration; Prophylaxis; Postbronchoscopy fever; Infectious complication

Introduction

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a useful modality in the pathological diagnosis of hilar and mediastinal lymphadenopathy caused by lung cancer [1-3], sarcoidosis [4], malignant lymphoma [5,6], and other diseases [7,8]. Recent reports indicate that the diagnostic sensitivity and accuracy of mediastinal lymph nodes in the staging of lung cancer by EBUS-TBNA were similar to the sensitivity and accuracy of mediastinoscopy, and the number of complications was fewer with EBUS-TBNA than with mediastinoscopy [9]. Another group of investigators showed that the diagnostic sensitivity of EBUS-TBNA for metastatic lymphadenopathy of lung cancer was higher than the sensitivity of positron emission tomography [10]. Moreover, the quality of samples from lymph nodes (LNs) obtained by EBUS-TBNA was sufficient for molecular testing, which included epidermal growth factor receptor mutation and the anaplastic lymphoma kinase fusion gene in lung cancer [11-13].

Although EBUS-TBNA is a relatively tolerable and safe procedure [14], infectious complications after EBUS-TBNA have been reported including mediastinitis, pneumonia, and pericarditis [15]. Infectious complications induced by EBUS-TBNA are often more serious than infections associated with conventional fiberoptic bronchoscopy, and precautions should be considered to prevent these infectious events. Whereas prior studies have not indicated the usefulness of antibiotics prophylaxis after conventional fiberoptic bronchoscopy, the efficacy of antibiotic prophylaxis especially after EBUS-TBNA remains unclear. Thus, the objective of this study was to evaluate the efficacy of antibiotic prophylaxis in preventing the frequency of postbronchoscopy fever and infectious complications after EBUS-TBNA, preliminarily.

Materials and Methods

Study design

This open-label, prospective, randomized controlled trial was conducted from January 2011 to December 2013 at the Department of Respiratory Medicine of Juntendo University Hospital (Tokyo, Japan) and at Iizuka Hospital (Fukuoka, Japan). The study protocol was reviewed by the independent ethics committee of the institutional review board at each center. All patients provided written informed consent. The trial was registered with UMIN (000008813).

Patients

The eligibility criteria for participation were an age of 20 years or older, adequate liver and renal function, and written informed consent to participate. The key exclusion criteria were a history of allergy to penicillin, suspected active bacterial infection, a body temperature (BT) above 37.8°C, and use of immunosuppressive or anticarcinogenic agents or non-steroidal anti-inflammatory drugs. Patients who had significant hematological, hepatic or renal abnormalities or who were pregnant or breast feeding were also excluded from the study.

*Corresponding author: Tetsutaro Nagaoka, Department of Respiratory Medicine, Juntendo University Graduate School of Medicine 2-1-1 Hongo Bunkyo-ku, Tokyo-113-8421, Japan, Tel: +81-3-5802-1063; E-mail: jnagaoka@juntendo.ac.jp
Received July 17, 2017; Accepted July 19, 2017; Published July 24, 2017


Copyright: © 2017 Takagi H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
patients’ comorbidities were assessed using the Charlson Comorbidity Index (CCI) [16].

**Endobronchial ultrasound-guided transbronchial needle aspiration and antibiotic treatment**

No patient was intubated with an endobronchial tube for EBUS-TBNA. After conventional fiberoptic bronchoscopy for intrabronchial anesthesia and observation, EBUS-TBNA was performed with a convex probe endobronchial ultrasound bronchoscope (BF-UC260FW; Olympus, Tokyo, Japan). A dedicated 21- or 22-gauge needle (NA-201SX-4021 and NA-201SX-4022, respectively; Olympus, Tokyo, Japan) was used for the punctures. The stations of the punctured LNs were #2R, #4R, #4L, #7, and bilateral #10 and #11. All procedures were performed as previously described [17].

In the antibiotics group, ampicillin/sulbactam (3 g, administered once) was intravenously administered 30 min before the puncture, followed by oral amoxicillin/clavulanate (250 mg, three times daily for 7 days). No antibiotic was administered to the control group. We selected the aforementioned antibiotics for prophylaxis because pathogenic bacteria in infectious complications associated with EBUS-TBNA were mostly caused by normal oral flora organisms, and the spectra of the selected antibiotics are sufficient for these bacteria.

**Outcome measurements**

The enrolled patients measured and recorded their own axillary BT after 12 h, and then 2 days, 3 days, 4 days, and 5 days after the procedure. We defined “fever” as a BT above 37.8°C, based on the definition in a previous textbook [18]. The primary outcome of this study was the inhibitory effects of antibiotic prophylaxis on postbronchoscopy fever after EBUS-TBNA. The secondary outcomes included the change in the white blood cell count (WBC) and C-reactive protein (CRP) value at baseline and after examination within 14 days and the frequency of pulmonary or mediastinal infections that required antibiotic treatment within 28 days. We also assessed the clinical characteristics of patients without fever or with fever after EBUS-TBNA. Risk factors of postbronchoscopy fever were evaluated by univariate analysis between the groups without and with fever with regard to smoking history, presence of comorbidities and antibiotic prophylaxis, the baseline WBC and CRP value, the number of punctures, and the presence of low-density areas in the LNs on computed tomography.

**Statistical analyses**

Sample size was calculated based on the primary outcome by Fisher Exact Test. After the conventional fiberoptic bronchoscopy, incidence of respiratory tract infection following the prophylactic antibiotics treatment was 0.7% [19], and frequency of postbronchoscopy fever treatment were 10.5-26.6% in past decade reports [20,21]. Based on these data, 102 patients (n=51 in each group) was required at 80% power and α=0.05 to determine the preventive effect of postbronchoscopy fever by antibiotic prophylaxis.

We used the chi-square test or the Mann–Whitney U test, as appropriate, to compare the patients’ characteristics. We analyzed the serial changes in the BT by using linear mixed models. Serial changes in the WBC and CRP values were compared by using the Wilcoxon signed-rank test. These analyses were performed using Statistical Package for Social Science (SPSS) Version 21 software (Chicago, IL). A p value less than 0.05 was considered significant.

**Results**

**Study profile and baseline characteristics**

One hundred fourteen patients were eligible for this study. 60 patients were assigned to the prophylactic antibiotic group and 54 patients were assigned to the control group (i.e., no antibiotics). Eleven patients in the control group did not proceed because of withdrawals or protocol violations, and 13 patients in the antibiotics group were excluded because of protocol violations after registration. In the end, 47 patients in the control group and 43 patients in the antibiotics group participated in this study (Figure 1). The baseline characteristics of both groups are shown in Table 1. Age, sex, and smoking history were similar in both groups. The CCI value, BT, WBC, and CRP value at baseline did not significantly differ between the groups.

**The effect of antibiotic prophylaxis on post-EBUS-TBNA fever**

The BT values after EBUS-TBNA are shown in Figure 2. Patients with a fever at baseline were excluded. Thus, we compared the BT after EBUS-TBNA between the group with and the group without prophylactic antibiotics. Body temperature was highest at 12 hours after...
EBUS-TBNA; it then gradually decreased. However, the BT did not significantly differ between the groups. A past report has shown that postbronchoscopy fever after fiberoptic bronchoscopy mostly occurred within 12 hours after the procedure [21]. Our result was consistent with previous data.

Other outcome measurements

The postprocedure WBC and CRP were measured at 10.2 (2 - 21) days in the control and 11.9 (2 - 24) days in the antibiotics group after EBUS-TBNA, respectively. Changes in the WBC and CRP value before and after EBUS-TBNA in the control and antibiotics groups are presented in Figure 3. The baseline and postprocedure WBC and CRP values did not differ between the two groups. The results of the EBUS-TBNA procedure are shown in Table 2. In both groups, frequency of postbronchoscopy fever after EBUS-TBNA were 9%, but EBUS-TBNA-associated infectious complications that required antibiotic treatment did not occur within 28 days in either group. The number of punctures did not significantly differ between the groups. The percentage of patients in both groups who were finally diagnosed by EBUS-TBNA was almost similar. The diagnostic sensitivity of malignant LNs metastasis was 92.3% in the control group and 91.7% in the antibiotics group. These data were consistent to those of previous reports [22].

Sarcoidosis was diagnosed by compatible pathological findings such as epithelioid granuloma without necrosis in addition to the clinical and radiological characteristics of sarcoidosis. The diagnostic sensitivity for sarcoidosis tended to be higher in the control group (92.3%) than in the antibiotics group (66.7%), but this difference was not significant between the groups. Diagnostic specificities of malignant LNs metastasis and sarcoidosis by EBUS-TBNA were 100% in both groups. Although a grade 1 diarrhea and rash by common terminology criteria for adverse events were observed only in antibiotics group, treatment of prophylactic antibiotics was tolerable (Table 3).
and tumor necrosis factor alpha (TNF-α) have also been reported in levels of inflammatory cytokines such as interleukin (IL)-1β, IL-6, fever may be because of the rise of inflammatory cytokines associated with TBNA. Previous reports showed that the cause of postbronchoscopy fever following EBUS-TBNA was still unknown, whereas the frequency after the conventional fiberoptic bronchoscopy was found in 10.6–22.6% of patients in past decade reports [20,21]. Whereas the frequency of postbronchoscopy fever) commonly occurs. Postbronchoscopy fever after EBUS-TBNA. This preliminary prospective study is the first report to evaluate the efficacy of antibiotic prophylaxis after EBUS-TBNA. The baseline characteristics of patients with and without fever were not different with regard to age, sex, presence of comorbidities, and antibiotic prophylaxis. There were also no differences in the WBC and CRP values at baseline, the number of punctures, and the frequency of low-density areas in LNs between the groups, although the smoking pack-year values were significantly higher in the group with fever than in the group without fever.

Discussion

This preliminary prospective study is the first report to evaluate the efficacy of antibiotic prophylaxis after EBUS-TBNA. The antibiotic treatment had no inhibitory effect on postbronchoscopy fever after EBUS-TBNA. Antibiotic prophylaxis also had no effect on the WBC and CRP value between baseline and postprocedure. The preventive effect of antibiotic prophylaxis on adverse infectious events was unclear because no serious EBUS-TBNA associated infectious complication occurred within 28 days in the groups with and without antibiotics. We were, first, interested in the preventive effect of antibiotic prophylaxis for the serious infectious complications after EBUS-TBNA. However, the frequency of infectious complications following EBUS-TBNA was unclear at the time we started this study, and it was difficult to determine the appropriate sample size for the clinical study. Thus, we focused the fever following EBUS-TBNA as a primary outcome, and planned this preliminary study to detect the efficacy of prophylactic antibiotics after EBUS-TBNA.

Temporary fever after diagnostic fiberoptic bronchoscopy (i.e., postbronchoscopy fever) commonly occurs. Postbronchoscopy fever after the conventional fiberoptic bronchoscopy was found in 10.6–22.6% of patients in past decade reports [20,21]. Whereas the frequency of postbronchoscopy fever following EBUS-TBNA was still unknown, our study showed firstly that 9.0% of patients had fever after EBUS-TBNA. Previous reports showed that the cause of postbronchoscopy fever may be because of the rise of inflammatory cytokines associated with tissue destruction and/or bacteremia [23]. The elevation of serum levels of inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α) have also been reported in patients who developed a fever above 38°C after bronchoscopy. There was a highly significant correlation between IL-6 value and the number of alveolar macrophages in BAL fluid [24]. On the other hand, it has been demonstrated that the frequency of bacteremia was 6.5%–8.2% after conventional fiberoptic bronchoscopy [20,25,26] and 7.0% after EBUS-TBNA (26), including some febrile patients. Coagulase negative staphylococcus was the most common pathogens and coagulase positive staphylococcus and streptococcus species were also in the blood culture after examinations. These pathogens were often detected in serious infections after EBUS-TBNA [27], and this result may suggest the possibility that bacteremia after EBUS-TBNA may lead to serious infectious complications.

No evidence exists concerning the usefulness of antibiotic prophylaxis after conventional fiberoptic bronchoscopy. A recent randomized study evaluated the effect of prophylactic oral amoxicillin/clavulanate on postbronchoscopy fever; however, the frequency of fever and the serum levels of pyrogenic cytokines did not differ between the control and antibiotic groups [28]. Another investigator has reported that the frequency of respiratory tract infections after bronchoscopy tended to be lower in the group with prophylactic treatment of azithromycin than in the control group; however, this finding was not significant statistically [19]. Based on these results, the British Thoracic Society Guidelines for diagnostic and therapeutic bronchoscopy does not recommend antibiotic prophylaxis after conventional fiberoptic bronchoscopy, except for patients with specific conditions such as postpneumectomy, postheart valve prosthesis implantation, and previous episode of infectious endocarditis [29,30]. Meanwhile, several infectious complications following EBUS-TBNA such as mediastinitis, pneumonia, and pericarditis have been reported [27]. These infectious events were often more serious than those occurring after conventional fiberoptic bronchoscopy, and surgical treatment was required in several cases because systemic antibiotics therapy was insufficient for controlling the infections. Therefore, respiratory physicians are interested in the necessity of antibiotic prophylaxis especially following EBUS-TBNA, and we guess that prophylactic antibiotics may be treated without definite criteria or evidences. One of secondary outcome was preventive effect of serious infectious complications by prophylactic antibiotics in this preliminary study, and those kind of infectious events did not occur. Recent large multicenter-retrospective studies have shown that serious infectious complications after EBUS-TBNA are very rare (0.16%–0.19%) [15,31]. It was unclear whether prophylactic antibiotics had been used to treat patients in past reviews; nevertheless, precautions against such rare complications may be unnecessary.

We also assessed clinical characteristics of patients with and without fever after EBUS-TBNA. Our results showed that existing of comorbidities and number of punctures were not risk factor of postbronchoscopy fever, and antibiotic treatment was also unrelated to the development of fever following EBUS-TBNA. Smoking pack-years was significantly higher in the group with fever than in the group without fever. Patients with a longer smoking history are included in the high-risk group with respiratory tract infection. We suspected febrile patients with smoking history after EBUS-TBNA might have acute episode of bronchitis, but serious infectious events did not occur even in those patients. Low-density areas in LNs, as detected by computed tomography scanning, generally indicate tissue necrosis. However, the puncture of LNs with low-density areas did not elevate the frequency of postbronchoscopy fever in this study. The risk of infectious complications after puncturing a cystic lesion was demonstrated in a past report [31]. Patient selection, thus, could be more important in preventing infectious adverse events. In addition, cleaning the oral

<table>
<thead>
<tr>
<th></th>
<th>Without fever (n=82)</th>
<th>With fever (n=8)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>58.9 ± 14.7</td>
<td>58.6 ± 13.4</td>
<td>0.989</td>
</tr>
<tr>
<td>Male sex</td>
<td>49 (60)</td>
<td>9 (100)</td>
<td>0.025</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoker</td>
<td>12 (15)</td>
<td>0</td>
<td>0.591</td>
</tr>
<tr>
<td>Pack-years</td>
<td>40.3 ± 27.6</td>
<td>76.7 ± 46.4</td>
<td>0.011</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>38 (46)</td>
<td>5 (63)</td>
<td>0.472</td>
</tr>
<tr>
<td>CCI</td>
<td>0.5 ± 0.9</td>
<td>1.0 ± 0.8</td>
<td>0.29</td>
</tr>
<tr>
<td>Patients with ABx</td>
<td>39 (48)</td>
<td>4 (50)</td>
<td>1</td>
</tr>
<tr>
<td>Blood tests</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WBC count (μL)</td>
<td>6.484 ± 2.624</td>
<td>6.541 ± 1.274</td>
<td>0.528</td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
<td>0.6 ± 1.1</td>
<td>3.0 ± 4.5</td>
<td>0.089</td>
</tr>
<tr>
<td>EBUS-TBNA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. aspirations</td>
<td>3.1 ± 1.5</td>
<td>3.9 ± 2.4</td>
<td>0.367</td>
</tr>
<tr>
<td>Lesions with necrosis</td>
<td>45 (55)</td>
<td>6 (63)</td>
<td>0.728</td>
</tr>
</tbody>
</table>

Table 3: Comparison of the clinical findings of patients with and without fever. The data are presented as the mean ± the standard deviation or as the mean (percentage), unless otherwise denoted. ABx: Antibiotics; CCI: Charlson Comorbidity Index; CRP: C-reactive Protein; EBUS-TBNA: Endobronchial Ultrasound-Guided Transbrachial Needle Aspiration; LN: Lymph Node; WBC: White Blood Cell.
mucosa and the aspiration needle before the puncture may be useful in reducing infectious complications associated with EBUS-TBNA.

There were several limitations in this study. First, preventive effect of serious infectious complications by antibiotic prophylaxis was still unclear, because the sample size of this preliminary study was too small for evaluation. Second, exclusion of over 20% of enrolled participants because of protocol violation decreased the quality of this study. Third, there were only two participating institutions, and the examination procedure may have been biased. Forth, the values of WBC and CRP may have been biased, because the time measuring blood test after EBUS-TBNA was not unified. Fifth, we did not evaluate bacteremia and inflammatory cytokines in any patient; thus, the causes of fever were unclear for each febrile patient.

Conclusion
The findings of this preliminary study and the low frequency of infectious complications, which has also been demonstrated in previous reports, suggest that antibiotic prophylaxis is not recommended for EBUS-TBNA as same with the guideline for conventional diagnostic fiberoptic bronchoscopy. Further investigation of the phenotype of patients with infectious complications after EBUS-TBNA may be useful to detect patients who need selective treatment by prophylactic antibiotics.

References